1. Upfront boost Gamma Knife 'leading-edge' radiosurgery to FLAIR MRI-defined tumor migration pathways in 174 patients with glioblastoma multiforme: a 15-year assessment of a novel therapy
- Author
-
Christopher Duma, Ryan M Casserly, Nathan Oh, Brian S. Kim, Marianne Plunkett, Christopher M Owen, Daniela Alexandru Abrams, Azzurra-Sky Riley, Ruslana Cannell, Alexa Smith, Ralph Mackintosh, Daniel J Furman, Robert O. Dillman, Gustavo Mendez, David Weiland, Marlon S. Mathews, Michael Brant-Zawadzki, Ami R Sanathara, Lian Stemler, Garrett Smith, Chad A. Caraway, Burton L. Eisenberg, and Peter Chen
- Subjects
Adult ,Time Factors ,medicine.medical_treatment ,Brain tumor ,Radiosurgery ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Cell Movement ,Glioma ,Multicenter trial ,Medicine ,Humans ,Aged ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,Temozolomide ,business.industry ,Brain Neoplasms ,Astrocytoma ,General Medicine ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Radiation therapy ,Treatment Outcome ,030220 oncology & carcinogenesis ,business ,Nuclear medicine ,Glioblastoma ,030217 neurology & neurosurgery ,medicine.drug ,Follow-Up Studies - Abstract
OBJECTIVEGlioblastoma multiforme (GBM) is composed of cells that migrate through the brain along predictable white matter pathways. Targeting white matter pathways adjacent to, and leading away from, the original contrast-enhancing tumor site (termed leading-edge radiosurgery [LERS]) with single-fraction stereotactic radiosurgery as a boost to standard therapy could limit the spread of glioma cells and improve clinical outcomes.METHODSBetween December 2000 and May 2016, after an initial diagnosis of GBM and prior to or during standard radiation therapy and carmustine or temozolomide chemotherapy, 174 patients treated with radiosurgery to the leading edge (LE) of tumor cell migration were reviewed. The LE was defined as a region outside the contrast-enhancing tumor nidus, defined by FLAIR MRI. The median age of patients was 59 years (range 22–87 years). Patients underwent LERS a median of 18 days from original diagnosis. The median target volume of 48.5 cm3 (range 2.5–220.0 cm3) of LE tissue was targeted using a median dose of 8 Gy (range 6–14 Gy) at the 50% isodose line.RESULTSThe median overall survival was 23 months (mean 43 months) from diagnosis. The 2-, 3-, 5-, 7-, and 10-year actual overall survival rates after LERS were 39%, 26%, 16%, 10%, and 4%, respectively. Nine percent of patients developed treatment-related imaging-documented changes due to LERS. Nineteen percent of patients were hospitalized for management of edema, 22% for resection of a tumor cyst or new tumor bulk, and 2% for shunting to treat hydrocephalus throughout the course of their disease. Of the patients still alive, Karnofsky Performance Scale scores remained stable in 90% of patients and decreased by 1–3 grades in 10% due to symptomatic treatment-related imaging changes.CONCLUSIONSLERS is a safe and effective upfront adjunctive therapy for patients with newly diagnosed GBM. Limitations of this study include a single-center experience and single-institution determination of the LE tumor target. Use of a leading-edge calculation algorithm will be described to achieve a consistent approach to defining the LE target for general use. A multicenter trial will further elucidate its value in the treatment of GBM.
- Published
- 2016